ClinicalTrials.gg
RecruitingNCT07436663SGLT2i/DPPiUpdated Oct 15, 2026

Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC

A Phase 4 interventional study of Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy and Sitagliptin (DPP4 inhibitor) in Breast Cancer, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Tanta University · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 15, 2026Now RecruitingFirst site in Egypt+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Breast Neoplasms by Tanta University — 4 open to participants now, 4 under way, 1 of them phase 3. Breast Neoplasms · Tanta University.

Planned enrollment
Largest of 14
150 · median 48
Started
2026
with 1 other
Phase 4
2 of 14
1 open now
Registered
11th of 14
by date

Among the 14 studies in Breast Neoplasms by Tanta University, this one has the largest planned enrollment, is one of 2 that started in 2026, is one of 2 in phase 4, and was the 11th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 14 studies in Breast Neoplasms by Tanta University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Breast Neoplasms by Tanta University, or all of them as a file.
02

Study summary

Background:

Breast cancer is the most frequently diagnosed malignancy among women worldwide and a major cause of morbidity and mortality. Anthracycline-based chemotherapy, particularly doxorubicin, remains a cornerstone of treatment; however, its clinical utility is limited by dose-dependent cardiotoxicity that can lead to irreversible cardiac dysfunction and heart failure. The search for effective cardioprotective interventions is therefore a key priority in cardio-oncology.

Aim:

This study aims to compare the efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors in preventing doxorubicin-induced cardiotoxicity in Egyptian women with breast cancer.

Methods:

A prospective, randomized, controlled clinical trial will be conducted at Oncology Hospital of Tanta University. Eligible adult female patients with histologically confirmed breast cancer scheduled to receive anthracycline-containing chemotherapy will be randomized into three groups: (1) control (standard care), (2) SGLT2 inhibitor group (dapagliflozin 10-25 mg daily), and (3) DPP-4 inhibitor group (sitagliptin 50-100 mg daily). Treatment will start five days before the first chemotherapy cycle and continue for six months, with follow-up for an additional six months. Cardiac function will be assessed by echocardiography (LVEF and GLS) and biomarkers (Cardiac Troponin T, and NT-proBNP). The primary endpoint is the incidence of cardiotoxicity defined by a ≥10% decline in LVEF to \<50% or a >15% relative decline in GLS accompanied by biomarker elevation.

Expected Outcomes:

It is anticipated that both SGLT2 and DPP-4 inhibitors will reduce the incidence and severity of doxorubicin-induced cardiotoxicity, with SGLT2 inhibitors expected to demonstrate superior cardioprotective efficacy. Findings from this study may support the integration of cardioprotective antidiabetic agents into oncology care pathways to improve the cardiac outcomes and overall survival of breast cancer patients.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female, ≥18 years, Egyptian nationality.
  2. Breast cancer (any stage) with planned anthracycline containing chemotherapy (intended cumulative DOX ≥240 mg/m² or epirubicin ≥360 mg/m² equivalents).
  3. Baseline echo suitable for ≥53%.
  4. Able to consent and comply with follow up.

Exclusion criteria

Exclusion Criteria:

    • Type 1 and type 2 diabetes; history of diabetic ketoacidosis; pregnancy/lactation.

      • Symptomatic HF, cardiomyopathy, significant valvular disease, prior anthracycline exposure.
      • Baseline hypotension (SBP \<95 mmHg), recurrent UTIs/mycotic infections, active foot ulcer/critical limb ischemia.
      • Inflammatory diseases, liver and kidney diseases.
      • diseases.
      • Other type of or diseases.
      • Patients who exposed to surgery less than one month.
      • Concomitant dexrazoxane planned upfront (allowed only for rescue; documented).
      • Known to study drugs.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Placebo comparator
    Arm A (Control)

    Usual care without prophylactic cardioprotective agent (guideline directed initiation permitted if clinically indicated post randomization; recorded and adjusted for).

    Other: Standard Care (in control arm)

  • Active comparator
    Arm B (SGLT2i)

    Dapagliflozin 10 mg orally once daily (dose may increase to 25 mg if tolerated after Cycle 1) starting ≥5 days before first DOX dose and continued for 3 months.

    Drug: Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy

  • Active comparator
    Arm C (DPP 4i)

    Sitagliptin 100 mg orally once daily (50 mg if eGFR 30-45 mL/min/1.73m²) starting ≥5 days before first DOX dose and continued for 3 months.

    Drug: Sitagliptin (DPP4 inhibitor)

Interventions

  • DrugDapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy

    Dapagliflozin 10 mg orally once daily (dose may increase to 25 mg if tolerated after Cycle 1) starting ≥5 days before first DOX dose and continued for 3 months.

  • DrugSitagliptinStudies of SitagliptinSitagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sitagliptin 100 mg orally once daily (50 mg if eGFR 30-45 mL/min/1.73m²) starting ≥5 days before first DOX dose and continued for 3 months.

  • OtherStandard Care (in control arm)

    Usual care without prophylactic cardioprotective agent (guideline directed initiation permitted if clinically indicated post randomization; recorded and adjusted for).

06

What researchers measure

Primary outcomes

  1. Percentage of participants experiencing cardiotoxicity

    Cardiotoxicity will be defined as the occurrence of any of the following during the study period: A decline in left ventricular ejection fraction (LVEF) ≥ 10% from baseline resulting in an LVEF \< 50%, as measured by echocardiography, or A relative reduction in global longitudinal strain (GLS) \> 15% from baseline, as assessed by speckle-tracking echocardiography. Unit of Measure: Percentage of participants experiencing cardiotoxicity (%)

    Time frame: Within 3 months from initiation of therapy.

Secondary outcomes

  1. Percentage Change in Left Ventricular Ejection Fraction (LVEF)

    Description: Absolute change in left ventricular ejection fraction from baseline to 3 months, measured by transthoracic echocardiography. Unit of Measure: Percentage points (%)

    Time frame: 3 months

  2. Percentage Change in Global Longitudinal Strain (GLS)

    Description: Relative percentage change in global longitudinal strain from baseline to 3 months, assessed using speckle-tracking echocardiography. Unit of Measure: Percentage (%)

    Time frame: 6 months

  3. Time to cardiotoxicity and HF hospitalization through 6 months.

    Time frame: 6 months

  4. Change in serum cardiac biomarker levels e.g., troponin

    Change in Cardiac Biomarkers (if applicable) Description: Change in serum cardiac biomarker levels (e.g., troponin) from baseline to 3 months. Troponin: ng/L

    Time frame: 3 months

  5. Change in serum cardiac biomarker levels (e.g., NT-proBNP)

    Description: Change in serum cardiac biomarker levels (e.g., NT-proBNP) from baseline to 3 months. NT-proBNP: pg/mL

    Time frame: 3 months

  6. All cause mortality and cancer therapy interruptions due to cardiac reasons.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Nov 2027, 21 months after the start.

Of 110 non-industry phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 21 months is below that.

Counting every sponsor, half of 130 studies reached it within 42 months; a quarter within 20 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Feb 27, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Nov 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
1 site added — first site in Egypt
Show site
  • Tanta University · Tanta, Egypt
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Egypt
    Show site
    • Tanta University · Tanta, Egypt
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07436663
Lead sponsor
Tanta University
Responsible party
Mai Abo Elyazeed Hassan Hamouda (Associate Lecturer, Delta University for Science and Technology) — Principal investigator
First posted
Feb 27, 2026
Start date
Feb 1, 2026
Primary completion
Nov 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Mai Aboelyazed Elgebaly, Associate Lecturer
Contact
dr.mai.elgebaly@gmail.com
+0201061412257 ext. 020
Mai Aboelyazed Elgebaly, Associate Lecturer
Contact
mai.elgebaly@deltauniv.edu.eg
+201115064114 ext. 020
Mohamed Abdelhamid Almeldein, Professor
principal investigator · Tanta University
Mohamed Elhussieny Shams, Professor
principal investigator · Mansoura University
Haidy Mahmoud Sami, Lecturer
study director · Delta University
Osama Hamid Shoaeb, Associate Professor
study director · Tanta University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion